Mechanisms by Which IGF-I May Promote Cancer

Overview

Journal Cancer Biol Ther

Specialties Oncology
Pharmacology

Date 2003 Dec 23

PMID 14688466

Citations 77

Authors

Adda Grimberg

Affiliations

Soon will be listed here.

Abstract

Multiple large case-control studies in the past five years have reported positive associations between high circulating levels of the insulin-like growth factor (IGF)-I and risk for different types of cancer. Correlations certainly do not prove causation, but the reproducibility of this finding implies this is a hypothesis worth further examination through more mechanistic studies. IGF-I binds to the IGF-I receptor, a tyrosine kinase receptor that transduces signals to the nucleus and mitochondrion primarily via the mitogen-activated protein kinase (MAPK) and PI3K/Akt pathways. Examples will be provided to illustrate how IGF-I signaling may contribute to each stage of cancer progression: malignant transformation, tumor growth, local invasion and distant metastases, and resistance to treatment. In addition to direct contributions to each of these stages, IGF-I may promote cancer indirectly, through interactions with oncogenes and tumor suppressors, interactions with other hormones (especially the sex steroids in breast and prostate cancers) and interactions with the IGF binding proteins (IGFBPs). Finally, circulating IGF-I may facilitate cancer development though it likely does not cause cancer to form. Prompted by the accumulating evidence, investigations are also being pursued to modulate the IGF system as a possible means of cancer prevention or treatment.

Citing Articles

Regulation of pro-apoptotic and anti-apoptotic factors in obesity-related esophageal adenocarcinoma.

Agrawal S, Podber A, Gillespie M, Dietz N, Hansen L, Nandipati K Mol Biol Rep. 2024; 51(1):1049.

PMID: 39395071 PMC: 11470870. DOI: 10.1007/s11033-024-09931-6.

Height and breast cancer risk in premenopausal Korean women aged under 40 years of age.

Tran T, Chang Y, Choi H, Kwon R, Lim G, Cho Y Br J Cancer. 2024; 131(12):1913-1918.

PMID: 39375531 PMC: 11628559. DOI: 10.1038/s41416-024-02846-w.

Losartan rewires the tumor-immune microenvironment and suppresses IGF-1 to overcome resistance to chemo-immunotherapy in ovarian cancer.

Sun Y, Yin Z, Li S, Wu L, Zhang Y, Zhao Y Br J Cancer. 2024; 131(10):1683-1693.

PMID: 39369055 PMC: 11554678. DOI: 10.1038/s41416-024-02863-9.

Decoding the Role of Insulin-like Growth Factor 1 and Its Isoforms in Breast Cancer.

Kotsifaki A, Maroulaki S, Karalexis E, Stathaki M, Armakolas A Int J Mol Sci. 2024; 25(17).

PMID: 39273251 PMC: 11394947. DOI: 10.3390/ijms25179302.

Circulating free insulin-like growth factor-I and prostate cancer: a case-control study nested in the European prospective investigation into cancer and nutrition.

Cheng T, Noor U, Watts E, Pollak M, Wang Y, McKay J BMC Cancer. 2024; 24(1):676.

PMID: 38831273 PMC: 11145848. DOI: 10.1186/s12885-023-11425-w.

References

Datta K, Nambudripad R, Pal S, Zhou M, Cohen H, Mukhopadhyay D . Inhibition of insulin-like growth factor-I-mediated cell signaling by the von Hippel-Lindau gene product in renal cancer. J Biol Chem. 2000; 275(27):20700-6. DOI: 10.1074/jbc.M909970199. View

Hursting S, Perkins S, Phang J, Barrett J . Diet and cancer prevention studies in p53-deficient mice. J Nutr. 2001; 131(11 Suppl):3092S-4S. DOI: 10.1093/jn/131.11.3092S. View

Plonowski A, Schally A, Letsch M, Krupa M, Hebert F, Busto R . Inhibition of proliferation of PC-3 human prostate cancer by antagonists of growth hormone-releasing hormone: lack of correlation with the levels of serum IGF-I and expression of tumoral IGF-II and vascular endothelial growth factor. Prostate. 2002; 52(3):173-82. DOI: 10.1002/pros.10105. View

Vainio H, Kaaks R, Bianchini F . Weight control and physical activity in cancer prevention: international evaluation of the evidence. Eur J Cancer Prev. 2003; 11 Suppl 2:S94-100. View

Yakar S, Liu J, STANNARD B, Butler A, Accili D, Sauer B . Normal growth and development in the absence of hepatic insulin-like growth factor I. Proc Natl Acad Sci U S A. 1999; 96(13):7324-9. PMC: 22084. DOI: 10.1073/pnas.96.13.7324. View

Dunn S, Kari F, French J, Leininger J, Travlos G, Wilson R . Dietary restriction reduces insulin-like growth factor I levels, which modulates apoptosis, cell proliferation, and tumor progression in p53-deficient mice. Cancer Res. 1997; 57(21):4667-72. View

Scotlandi K, Maini C, Manara M, Benini S, Serra M, Cerisano V . Effectiveness of insulin-like growth factor I receptor antisense strategy against Ewing's sarcoma cells. Cancer Gene Ther. 2002; 9(3):296-307. DOI: 10.1038/sj.cgt.7700442. View

Yoon A, Hurta R . Insulin like growth factor-1 selectively regulates the expression of matrix metalloproteinase-2 in malignant H-ras transformed cells. Mol Cell Biochem. 2001; 223(1-2):1-6. DOI: 10.1023/a:1017549222677. View

STEPHEN R, Shaw L, Larsen C, Corcoran D, Darbre P . Insulin-like growth factor receptor levels are regulated by cell density and by long term estrogen deprivation in MCF7 human breast cancer cells. J Biol Chem. 2001; 276(43):40080-6. DOI: 10.1074/jbc.M105892200. View

10.

Dunn S, Torres J, Oh J, Cykert D, Barrett J . Up-regulation of urokinase-type plasminogen activator by insulin-like growth factor-I depends upon phosphatidylinositol-3 kinase and mitogen-activated protein kinase kinase. Cancer Res. 2001; 61(4):1367-74. View

11.

Grimberg A, Liu B, Bannerman P, El-Deiry W, Cohen P . IGFBP-3 mediates p53-induced apoptosis during serum starvation. Int J Oncol. 2002; 21(2):327-35. PMC: 4152903. View

12.

Nakagawa H, Chadwick R, Peltomaki P, Plass C, Nakamura Y, de la Chapelle A . Loss of imprinting of the insulin-like growth factor II gene occurs by biallelic methylation in a core region of H19-associated CTCF-binding sites in colorectal cancer. Proc Natl Acad Sci U S A. 2000; 98(2):591-6. PMC: 14632. DOI: 10.1073/pnas.98.2.591. View

13.

Braczkowski R, Schally A, Plonowski A, Varga J, Groot K, Krupa M . Inhibition of proliferation in human MNNG/HOS osteosarcoma and SK-ES-1 Ewing sarcoma cell lines in vitro and in vivo by antagonists of growth hormone-releasing hormone: effects on insulin-like growth factor II. Cancer. 2002; 95(8):1735-45. DOI: 10.1002/cncr.10865. View

14.

Bohula E, Salisbury A, Sohail M, Playford M, Riedemann J, Southern E . The efficacy of small interfering RNAs targeted to the type 1 insulin-like growth factor receptor (IGF1R) is influenced by secondary structure in the IGF1R transcript. J Biol Chem. 2003; 278(18):15991-7. DOI: 10.1074/jbc.M300714200. View

15.

Werner H, Shen-Orr Z, Rauscher 3rd F, Morris J, Roberts Jr C, LeRoith D . Inhibition of cellular proliferation by the Wilms' tumor suppressor WT1 is associated with suppression of insulin-like growth factor I receptor gene expression. Mol Cell Biol. 1995; 15(7):3516-22. PMC: 230588. DOI: 10.1128/MCB.15.7.3516. View

16.

Ricort J, BINOUX M . Insulin-like growth factor (IGF) binding protein-3 inhibits type 1 IGF receptor activation independently of its IGF binding affinity. Endocrinology. 2001; 142(1):108-13. DOI: 10.1210/endo.142.1.7915. View

17.

DiGiovanni J, Kiguchi K, Frijhoff A, Wilker E, Bol D, Beltran L . Deregulated expression of insulin-like growth factor 1 in prostate epithelium leads to neoplasia in transgenic mice. Proc Natl Acad Sci U S A. 2000; 97(7):3455-60. PMC: 16261. DOI: 10.1073/pnas.97.7.3455. View

18.

Hwa V, Oh Y, Rosenfeld R . The insulin-like growth factor-binding protein (IGFBP) superfamily. Endocr Rev. 1999; 20(6):761-87. DOI: 10.1210/edrv.20.6.0382. View

19.

Tang Y, Zhang D, Fallavollita L, Brodt P . Vascular endothelial growth factor C expression and lymph node metastasis are regulated by the type I insulin-like growth factor receptor. Cancer Res. 2003; 63(6):1166-71. View

20.

Pollak M . Insulin-like growth factor physiology and cancer risk. Eur J Cancer. 2000; 36(10):1224-8. DOI: 10.1016/s0959-8049(00)00102-7. View